HAART decreases the frequency of CD16+ Mo [10], reduces HIV levels in brain, and improves neurocognitive function [19], but neurocognitive impairment (NCI) still occurs in ∼10–20% of AIDS patients [19], [20], [21]. This evidence concerns the gene FCGR3B and AIDS.